MYND Life Sciences Inc.
MYND
CNSX
| 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -277.00K | -191.30K | -276.10K | 345.40K | -397.90K |
| Total Depreciation and Amortization | 100.00 | 500.00 | 500.00 | 700.00 | 700.00 |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 27.40K | 56.50K | -- | -766.30K | 162.20K |
| Change in Net Operating Assets | 248.60K | 163.60K | 247.20K | 292.80K | 196.90K |
| Cash from Operations | -900.00 | 29.30K | -28.40K | -127.40K | -38.10K |
| Capital Expenditure | 1.00K | -1.00K | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | 164.30K | -- |
| Other Investing Activities | -1.00K | 1.00K | -- | 0.00 | 0.00 |
| Cash from Investing | 0.00 | 0.00 | -- | 164.30K | 0.00 |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | 50.00K |
| Repurchase of Common Stock | -- | -- | -- | -50.00K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -36.80K | 37.50K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.00K | 29.40K | -28.40K | 100.00 | -600.00 |